Biotop-report 2013
Yüklə 0,8 Mb. Pdf görüntüsü
|
- Bu səhifədəki naviqasiya:
- Editor
- Dr. Kai Bindseil Dr. Kai Bindseil
- MARCH 2012
- SEPTEMBER 2012
- OCTOBER 2012
| BioTOPics 46 | September 2013 BioTOP-Report Editorial Unique Chances to Create Value in Biotechnology and Life Sciences 3 Biotechnology More Companies, More Employees and New Deals 4 Pharma The German Capital Region: Highly Attractive for the Pharmaceutical Industry 14 Diagnostics An Excellent Location for the Development of Innovative Diagnostics 18 Industrial Biotechnology Focus: Biopolymers and Bio-based Plastics 22 Global Business New Markets and Horizons for Global Business 25 Business Location Excellent Services for Berlin-Brandenburg 28 Technology Transfer Technology Transfer between Science and Business 30 Life Sciences A Science and Research Hub 34 Know-how in Systems Medicine and Systems Biology 36 Biotech 2020+ 41 Biotech Parks The BioCampus Network Berlin-Brandenburg 50
Addresses 55
Fasanenstraße 85 · 10623 Berlin · Germany · Phone +49 30 318622–0 · Fax +49 30 318622–22 · biotop@biotop.de · www.healthcapital.de
Page 10 Ralfpoller*, Wladimir Bulgar*; Page 13 Werner Popp (Profile organobalance), Vanillla * (Profile BPI); Page 14 Phartisan*, Idrutu*; Page 18 Stratum*, Stanislav Perov*; Page 20 Alx, fotolia.com (Profile Dr. Nothgi); Page 22 BASF; Page 25 C. Keating*, Moth*; Seite 32 Bayer HealthCare; Page 33 Eric1513*, Jankaliciak*, Grafoo*, Eraxion*, Kjpargeter*, Andrey Armyagov*; Page 37 Christoph Heidrich; Page 40 Illustration: webersupiran, photo Sofiaworld *; Page 41 Paulus Rusyanto*, Collpicto*, 18percentgrey*; Page 46 Natalia Pavlichenko*/Patho (Profile Predemtec) *dreamstime.com Content
3 BioTOPics 46 | September 2013 BioTOP-Report Editorial The German Capital Region – Unique Chances to Create Value in Biotechnology and Life Sciences In an emerging health environment, manufacturers of drugs, diagnostics and devices will need to be able to prove not only the safety and efficacy but also the value of their products. Thus all players in the value chain – reaching from scientific institutions and biotech companies to clinics and healthcare providers – are rethinking their products, services and business models. They find perfect conditions in Berlin-Brandenburg. Obviously, most participants in the value chain have realised that cooperation is the most important factor for success and are shap- ing their cooperation strategies:
k Cross-innovation at the interface of life sciences, information technology and engineering takes place everywhere. This innovation sector will not only create value through new tools and cost reduction in healthcare delivery, but also enable all of us to take control of our own health and wellness. The most recent example is the Joint Lab for Bioelectronics of the Technische Universität Berlin and the Leibniz Institute for Microelectronics.
k
Molecular Medicine (MDC) and the Charité – Universitäts- medizin Berlin will come together in the Berlin Institute of Health (BIH) to create the new flagship of German life sci- ences.
k Scientific excellence and development experience will team up in the CoLaborator, established by Bayer to incubate start- ups.
k Entrepreneurial skills will be strengthened in the Entrepre- neurial Network University of the Freie Universität Berlin, Charité and several companies. Berlin-Brandenburg is indeed the European hotspot for collab- oration. More than 200 biotechnology and 30 pharmaceutical companies benefit from close cooperation with five universities and more than a dozen institutes of the Helmholtz, Max Planck, Fraunhofer and Leibniz societies and associations, as well as more than 130 hospitals – among them Europe’s largest univer- sity hospital: Charité – Universitätsmedizin Berlin. As a consequence, the sector has grown more than 6% in 2012 and is growing continuously since 10 years. This fertile ground will be further strengthened with the new master plan for the healthcare industry. BioTOP is pleased to present the most im- portant developments in life sciences, pharma and biotechnology in our new annual report. We hope you enjoy reading our report, and we invite you to play an active role in one of the most vibrant European life sciences networks. Don’t hesitate to contact us. Dr. Kai Bindseil Dr. Kai Bindseil Cluster Manager HealthCapital Director BioTOP Berlin-Brandenburg bindseil@biotop.de www.healthcapital.de
4 BioTOPics 46 | September 2013 BioTOP-Report Biotechnology More Companies, More Employees and New Deals The positive development of the regional corporate landscape got new momentum in 2012. The number of employees in the sector rose by 6.5 %. Compared to average growth rates of 3.5% during recent years, this has been a clear and very welcome sign of the dynamism in the Berlin-Brandenburg region, where 222 companies now employ a workforce numbering 4,348 people. Development of the Companies in 2012 BioTOP conducted its anual survey of regional companies for the year 2012 to obtain a comprehensive overview of the current development of the corporate scene. During 2012, twelve new companies joined the ranks of surveyed companies, of which nine were newly founded and three included in the survey for the first time. Five companies ceased operations or moved to a different region. The new companies are still smaller firms focus- ing on services and product development in the field of biomed- icine. As an example, we refer to t-cell Europe, which received funding from the High-Tech Gründerfonds (HTGF). The aim of t-cell Europe, a spin-off of the Berlin-Brandenburg Centre for Re- generative Therapies, is to use its patented platform technology to develop and market new t-cell-based regenerative therapies. The company’s first reference product will be a t-cell product for kidney transplants. Another interesting start-up is Drug Response Dx GmbH in Hennigsdorf. DRDx is developing a robust compan- ion diagnostic test which permits secure stratification regarding failure in TNF α blocker (TBA) therapy for rheumatism patients and therefore addresses a very big market. The sizes of companies barely changed during the past few years. Smaller enterprises with less than ten employees make up 63% of all companies, but these firms also account for only app. 15% of all employees. More than 54% of those employed in the re- gional biotech sector work in the 19 companies with more than 50 employees. The thematic focus of the industry also remained unchanged during recent years and continues lie on biomedicine, and here particularly diagnostics. MARCH 2012 10. BIONNALE in Berlin – 10 years of success – Biggest biotech industry meet- ing in Berlin-Brandenburg celebrates its jubilee
NOXXON's NOX-A12 delays recidivation in preclinical glioblastoma model ++++ Epigenomics AG enrolls first participant in its FIT comparative study with Epi proColon ®
MOLOGEN AG: Promising start in financial year 2012, quarterly record pre- sented
++++ ifp and Romer Labs join in world-wide sales cooperation for EnzymeFast ® food test kits JUNE 2012 ORGANOBALANCE presents new research results on ACHEMA 2012: Extend- ed application range for yeast strains in biotechnological production ++++
CellTrend GmbH and One Lambda Inc. agree to world-wide sales contract ++++
United States Patent and Trademark Office grants co.don AG patent for production of autologous spinal disc cell transplants ++++ NOXXON initiates phase IIa study of anti-CCL2/MCP-1 Spiegelmer ® NOX-E36 for treatment of diabetic neuropathy ++++
ATLAS Biolabs extends spectrum of services by Variant AnalysisTM and iReportTM by Ingenuity ® Systems for data analysis and interpretation JULY 2012 Epigenomics appreciates reimbursement of Septin-9 blood test for early rec- ognition of colon cancer by Swiss Life in France ++++
MOLOGEN AG capital increase of 22 million Euros AUGUST 2012 co.don
® AG reaches another milestone on the path to central approval; Recruit- ment phase for clinical phase II trial completed successfully ++++
Merck buys Biochrom AG ++++ Indian pharma firm Piramal invests in molecular imaging in Germany SEPTEMBER 2012 Epigenomics AG announces changes in executive board ++++ Charité and Sanofi extend partnership by diabetes alliance ++++
MOLOGEN AG: Current data of kidney cancer therapy MGN1601 shows further improved results OCTOBER 2012 50 years Klosterfrau Berlin GmbH ++++ ATLAS Biolabs takes part in European projects on the research of DNA repair and cell aging ++++
co.don ® AG from Teltow presents gentle alternative – preserve joints instead of replacing them Yüklə 0,8 Mb. Dostları ilə paylaş:
|